147 related articles for article (PubMed ID: 38072961)
1. Learning from cerebrospinal fluid drug-resistant HIV escape-associated encephalitis: a case report.
Kang J; Wang Z; Zhou Y; Wang W; Wen Y
Virol J; 2023 Dec; 20(1):292. PubMed ID: 38072961
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic HIV CNS viral escape among patients on effective cART.
Manesh A; Barnabas R; Mani S; Karthik R; Abraham OC; Chacko G; Kannangai R; Varghese GM
Int J Infect Dis; 2019 Jul; 84():39-43. PubMed ID: 30951880
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.
Edén A; Fuchs D; Hagberg L; Nilsson S; Spudich S; Svennerholm B; Price RW; Gisslén M
J Infect Dis; 2010 Dec; 202(12):1819-25. PubMed ID: 21050119
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.
Peluso MJ; Ferretti F; Peterson J; Lee E; Fuchs D; Boschini A; Gisslén M; Angoff N; Price RW; Cinque P; Spudich S
AIDS; 2012 Sep; 26(14):1765-74. PubMed ID: 22614889
[TBL] [Abstract][Full Text] [Related]
5. HIV positive patient with HSV-2 encephalitis: case report.
Pagliano P; Ascione T; Carleo MA; Boccia G; De Caro F; Tortora F
Infez Med; 2016 Sep; 24(3):245-9. PubMed ID: 27668908
[TBL] [Abstract][Full Text] [Related]
6. Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.
Joseph SB; Kincer LP; Bowman NM; Evans C; Vinikoor MJ; Lippincott CK; Gisslén M; Spudich S; Menezes P; Robertson K; Archin N; Kashuba A; Eron JJ; Price RW; Swanstrom R
Clin Infect Dis; 2019 Sep; 69(8):1345-1352. PubMed ID: 30561541
[TBL] [Abstract][Full Text] [Related]
7. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39).
Imaz A; Niubó J; Amara A; Khoo S; Ferrer E; Tiraboschi JM; Acerete L; Garcia B; Vila A; Podzamczer D
J Neurovirol; 2018 Aug; 24(4):391-397. PubMed ID: 29542028
[TBL] [Abstract][Full Text] [Related]
9. Viral escape in the CNS with multidrug-resistant HIV-1.
Béguelin C; Vázquez M; Bertschi M; Yerly S; de Jong D; Rauch A; Cusini A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19745. PubMed ID: 25397490
[TBL] [Abstract][Full Text] [Related]
10. HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape.
Bingham R; Ahmed N; Rangi P; Johnson M; Tyrer M; Green J
Int J STD AIDS; 2011 Oct; 22(10):608-9. PubMed ID: 21998185
[TBL] [Abstract][Full Text] [Related]
11. Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States.
Mukerji SS; Misra V; Lorenz DR; Uno H; Morgello S; Franklin D; Ellis RJ; Letendre S; Gabuzda D
Clin Infect Dis; 2018 Sep; 67(8):1182-1190. PubMed ID: 29617912
[TBL] [Abstract][Full Text] [Related]
12. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
García F; Alonso MM; Romeu J; Knobel H; Arrizabalaga J; Ferrer E; Dalmau D; Ruiz I; Vidal F; Frances A; Segura F; Gomez-Sirvent JL; Cruceta A; Clotet B; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
J Acquir Immune Defic Syndr; 2000 Sep; 25(1):26-35. PubMed ID: 11064501
[TBL] [Abstract][Full Text] [Related]
13. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.
Letendre SL; Mills AM; Tashima KT; Thomas DA; Min SS; Chen S; Song IH; Piscitelli SC;
Clin Infect Dis; 2014 Oct; 59(7):1032-7. PubMed ID: 24944232
[TBL] [Abstract][Full Text] [Related]
14. Diffuse White Matter Signal Abnormalities on Magnetic Resonance Imaging Are Associated With Human Immunodeficiency Virus Type 1 Viral Escape in the Central Nervous System Among Patients With Neurological Symptoms.
Kugathasan R; Collier DA; Haddow LJ; El Bouzidi K; Edwards SG; Cartledge JD; Miller RF; Gupta RK
Clin Infect Dis; 2017 Apr; 64(8):1059-1065. PubMed ID: 28329096
[TBL] [Abstract][Full Text] [Related]
15. Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.
Dravid AN; Natrajan K; Kulkarni MM; Saraf CK; Mahajan US; Kore SD; Rathod NM; Mahajan US; Wadia RS
Medicine (Baltimore); 2018 Feb; 97(8):e9969. PubMed ID: 29465595
[TBL] [Abstract][Full Text] [Related]
16. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Paton NI; Musaazi J; Kityo C; Walimbwa S; Hoppe A; Balyegisawa A; Asienzo J; Kaimal A; Mirembe G; Lugemwa A; Ategeka G; Borok M; Mugerwa H; Siika A; Odongpiny ELA; Castelnuovo B; Kiragga A; Kambugu A;
Lancet HIV; 2022 Jun; 9(6):e381-e393. PubMed ID: 35460601
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects.
Pérez-Valero I; Ellis R; Heaton R; Deutsch R; Franklin D; Clifford DB; Collier A; Gelman B; Marra C; McCutchan JA; Navis A; Sacktor N; Simpson D; Grant I; Letendre S
AIDS; 2019 Mar; 33(3):475-481. PubMed ID: 30702516
[TBL] [Abstract][Full Text] [Related]
19. CSF Inflammation Markers Associated with Asymptomatic Viral Escape in Cerebrospinal Fluid of HIV-Positive Individuals on Antiretroviral Therapy.
Guha D; Misra V; Yin J; Gabuzda D
Viruses; 2023 Aug; 15(9):. PubMed ID: 37766236
[TBL] [Abstract][Full Text] [Related]
20. Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.
Edén A; Nilsson S; Hagberg L; Fuchs D; Zetterberg H; Svennerholm B; Gisslén M
J Infect Dis; 2016 Dec; 214(12):1822-1825. PubMed ID: 27683820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
